



GEORGIA DEPARTMENT  
OF COMMUNITY HEALTH

# Georgia Department of Community Health

## DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health

**January 17, 2024**



**DRUG UTILIZATION REVIEW BOARD MEETING  
AGENDA**

*2 Martin Luther King Jr. Drive, S.E.*

*Atlanta, Georgia 30334*

*Department of Community Health Board Room - Room 470-A*

*East Tower, Balcony Level*

**Wednesday, January 17, 2024**

**10:00 a.m. to 2:00 p.m.**

**CALL TO ORDER**

*Celeste Fowler, PharmD, MBA, Chair*

**MINUTES FROM PREVIOUS MEETING**

*Chair*

**EXTERNAL COMMENTS SESSION**

*Chair*

**CLINICAL REVIEWS**

*Afzal Mistry, PharmD, NorthStar*

*Chad Nicholson, PharmD, NorthStar*

*Emily Baker, PharmD, BCPS, NorthStar*

➤ **New Drugs**

- Elevidys
- Inpefa
- Roctavian
- Veozah
- Zavzpret

**ADJOURNMENT OF OPEN SESSION**

*Chair*

**EXECUTIVE SESSION**

*Nina Bandali, PharmD, Pharmacist Account  
Manager, Magellan Rx Management*

**RECONVENING OF OPEN SESSION**

*Chair*

**BOARD'S RECOMMENDATIONS AND VOTES**

*Chair*

**FUTURE AGENDA ITEMS**

*Chair*

**ADJOURNMENT OF MEETING**

*Chair*

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES  
Tuesday, September 26, 2023**

**MEMBERS PRESENT**

M. Celeste Fowler, Pharm.D., HCMBA, Chair  
Gurinder Doad, M.D., Ph.D., Vice-Chair  
Doug Collins, M.D.  
Alton Condra, III, R.Ph.  
Torey Jones, Pharm.D.  
Burton L. Lesnick, M.D., FAAP  
Robyn Lorys, Pharm.D.  
J. Russell (Rusty) May, Pharm.D.  
Osgood (Drew) A. Miller, R.Ph.  
Danny A. Toth, R.Ph.  
Suzanne Walton, Pharm.D., BCPS, BCOP

**MEMBERS ABSENT**

Glenda Wrenn Gordon, M.D., MSHP, FAPA  
Otto Goyco, M.D.  
Matthew Perri, Pharm.D., R.Ph., Ph.D.  
Brent L. Rollins, R.Ph., Ph.D.

**Staff**

Peter D'Alba, Pharm.D., Pharmacy Director, Pharmacy Services  
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services  
Ashlee Henry, MSHI, Pharmacy Operations Supervisor  
Rose Duncan, MBA, Operations Analyst-Drug Rebate Program, Pharmacy Services  
Lori Garner, MHS, MBA, R.Ph., Pharmacist, SHBP  
Karla Forbes, Pharm.D., Program Integrity  
Keema McClean-Haynes, CPhT, Program Integrity

**NorthStar HealthCare Consulting**

Emily Baker, Pharm.D., BCPS, MHA, MBA, President  
Afzal "Fez" Mistry, Pharm.D., Clinical Programs Director  
Chad Nicholson, Pharm.D., Clinical Pharmacist  
Catherine "Amy" Baker, Pharm.D., Clinical Pharmacist

**OptumRx**

Mark Hall, MBA, PMP, Assoc. Director, Government and Public Sector Markets  
Talmahjia "Tami" Sweat, Pharm.D., Clinical Consulting

**Magellan Rx Management**

Nina Bandalí, Pharm.D., Pharmacist Account Manager

**Care Management Organizations**

Turkesia Robertson-Jones, Pharm.D., CareSource

Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES

Tuesday, September 26, 2023

**Call to Order**

The Drug Utilization Review Board (DURB/DUR Board/Board) held its third meeting for the calendar year virtually on September 26, 2023 via Zoom. The Chair, M. Celeste Fowler, Pharm.D., HCMBA, called the meeting to order at 10:10am after Board members introduced themselves.

**Minutes from the Previous Meeting**

Chair Fowler asked for corrections or changes to the minutes from the June 13, 2023 meeting. A motion was made (Burton L. Lesnick, M.D., FAAP) and seconded (J. Russell (Rusty) May, Pharm.D.) and carried to approve the minutes as written.

**External Comments Session**

The following external comment was presented to the Board:

- Chair Celeste Fowler read a letter submitted by Nancy Pitra (Director of Government Affairs) from the Alzheimer's Association to allow equitable access to Leqembi.

**New Drug Reviews**

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Multiple Sclerosis Agents	<i>Briumvi</i>	Afzal "Fez" Mistry, Pharm.D.
Alzheimer's Agents	<i>Leqembi</i>	Afzal "Fez" Mistry, Pharm.D.
HIV/AIDS	<i>Sunlenca</i>	Chad Nicholson, Pharm.D.
Disease Modifier, T1DM	<i>Tzield</i>	Chad Nicholson, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Briumvi
  - Comparability to Ocrevus and other products – some indirect comparisons but hard to determine which is more potent since no head-to-head studies; rely on expert consensus and refer to agents that have already been on the market
  - Agents for Relapsing Remitting – not really looking at symptoms but choice depends on patient and physician determining what would lead to best adherence for patient

Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES  
Tuesday, September 26, 2023

- Leqembi
  - Study trials excluded patients if any bleeding risks
  - At least three MRIs required to monitor for amyloid related imaging abnormalities (ARIA); Pet Scan and MRI required prior to treatment
  - Stratification to determine mild vs. advanced disease – mainly look at patient or caregiver reported systems, scans.
  - Phase IV trials – open label extended study ongoing
  - HEAD Study – looking at early disease (amyloid elevation without Alzheimer symptoms)
  - Will check with manufacturer if looking at targeting certain biomarkers
  - Difficult to stratify which patients to give these drugs to; a lot of unknown
  - Modest cognitive decline but translates to 4-5 months delay in disease progression
  - Trickier situation if patient doesn't have cognitive symptoms
  - Concerns about use of drug in men vs. women; mostly used in women who aren't affected as much by cognitive decline
  - Minority population underrepresented in trials
- Sunlenca
  - Give consideration to frequency of dosing (when comparing with Trozargo); offers convenience and flexibility; advantage for compliance
- Tzield
  - Stage 2 screening – testing for autoantibodies not routine; now pushing to have more routine screening
  - Off label to reduce insulin requirements; not approvable criteria but can monitor; no data on impact of another dose
  - Exciting development; may be difficult to find patients
  - Rise in diagnosis seen after influenza and COVID infections, so this time frame may offer window of opportunity to identify patients
  - Didn't see study treatment protocols for prophylaxis of secondary infections (e.g. CMV)
  - 14 day regimen – daily outpatient infusions, transportation could be problematic

**DCH Decisions**

DCH Decisions from the June 2023 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

**Upcoming Meetings**

The following upcoming meetings were announced:

- Drug Utilization Review Board  
2 Martin Luther King Jr. Drive, SE  
East Tower  
Atlanta, Georgia 30334  
(\*Conducted via Zoom Webinars until further notice\*)

TBD

Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES

Tuesday, September 26, 2023

**Disclosure Forms**

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

**Adjournment of Open Session**

The DUR Board voted to have the Executive Session pursuant to the Open Meetings Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Magellan Rx Management, NorthStar HealthCare Consulting, and OptumRx. A motion was made by Burton L. Lesnick, M.D., FAAP and seconded (Danny A. Toth, R.Ph.) to approve the closed session. There was a unanimous vote approving the closed session. The Chair, M. Celeste Fowler, Pharm.D., HCMBA, adjourned the open session at approximately 11:48am, at which time members took a break then reconvened for the executive (closed) session.

**Executive Session**

The Executive Session was held from 11:53am to 12:18pm.

**Reconvening of Open Session**

The DUR Board reconvened for the open session at 12:28pm.

**Board's Recommendations to the Department**

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) or Physician Administered Drug List (PADL) as noted in Attachment A. All motions and votes are noted in Attachment B.

**Future Agenda Items**

There were no future agenda items noted.

**Conclusion**

At the conclusion of the open session and no other business for discussion, Chair Fowler adjourned the meeting at 12:36pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE \_\_\_\_\_ DAY  
OF \_\_\_\_\_, 2023.

---

M. Celeste Fowler, Pharm.D., HCMBA, Chair

Drug Utilization Review Board  
Motions - Votes - New Drugs  
September 26, 2023

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Multiple Sclerosis Agents		Briumvi (Intravenous) Injection	N/A	P/PA on PADL		
Board Members - Present		Motion Maker (v)	Seconded By (v)	YES (v)	NO (v)	ABSTAIN (v)
(Strike out when absent)						
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			✓		
3	Doad, Gurinder J.S., M.D., Ph.D. -Vice-Chair			✓		
4	Fowler, M. Celeste, Pharm.D., HCMAA-Chair					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.					
8	Lesnick, Burton, M.D., FAAP	✓		✓		
9	Loy, Robyn, Pharm.D.			✓		
10	May, J. Russell (Rusty), Pharm.D.		✓	✓		
11	Miller, Osgood (Drew) A., R.Ph.			✓		
12	Peri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.			✓		
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			✓		
TOTAL				8	0	0
New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Alzheimer's Agents		Leqembi (Intravenous) Injection	N/A	NP/PA on PADL		
Board Members - Present		Motion Maker (v)	Seconded By (v)	YES (v)	NO (v)	ABSTAIN (v)
(Strike out when absent)						
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.					
3	Doad, Gurinder J.S., M.D., Ph.D. -Vice-Chair					
4	Fowler, M. Celeste, Pharm.D., HCMAA-Chair					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.					
8	Lesnick, Burton, M.D., FAAP			✓		
9	Loy, Robyn, Pharm.D.	✓		✓		
10	May, J. Russell (Rusty), Pharm.D.			✓		
11	Miller, Osgood (Drew) A., R.Ph.		✓	✓		
12	Peri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.			✓		
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			✓		
TOTAL				6	0	0

Drug Utilization Review Board  
Motions - Votes - New Drugs  
September 26, 2023

New Drug		Drug	PDL Status	Motion - Recommendations		Additional Comments
HIV/AIDS		Sunlenca (Oral) Tablet	N/A	NP/PA on PDL		
Sunlenca (Subcutaneous) Injection			N/A	NP/PA on PADL		
Board Members - Present (Strike out, when absent)		Motion Maker (v)	Seconded By (v)	VOTES YES (v) NO (v) ABSTAIN (v)		
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.	✓				
3	Doad, Gurinder J.S., M.D., Ph.D.-Vice-Chair			✓		
4	Fowler, M. Celeste, Pharm.D., HCMB-A-Chair					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.					
8	Lesnick, Burton, M.D., FAAP			✓		
9	Loyls, Robyn, Pharm.D.			✓		
10	May, J. Russell (Rusty), Pharm.D.			✓		
11	Miller, Osgood (Drew) A., R.Ph.			✓		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.		✓	✓		
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			✓		
TOTAL				7		0
New Drug		Drug	PDL Status	Motion - Recommendations		Additional Comments
HIV/AIDS		Trogarzo (Intravenous) Injection	P/PA on PADL	NP/PA on PADL		
Board Members - Present (Strike out, when absent)		Motion Maker (v)	Seconded By (v)	VOTES YES (v) NO (v) ABSTAIN (v)		
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.	✓				
3	Doad, Gurinder J.S., M.D., Ph.D.-Vice-Chair			✓		
4	Fowler, M. Celeste, Pharm.D., HCMB-A-Chair					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.					
8	Lesnick, Burton, M.D., FAAP			✓		
9	Loyls, Robyn, Pharm.D.			✓		
10	May, J. Russell (Rusty), Pharm.D.			✓		
11	Miller, Osgood (Drew) A., R.Ph.			✓		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.		✓	✓		
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			✓		
TOTAL				7		0



Drug Utilization Review Board  
Motions - Votes - New Drugs  
September 26, 2023

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Disease Modifier, T1DM		Tzield (Intravenous) Injection	N/A	NP/PA on PADL		
Board Members - Present (Strike out, when absent)		Motion Maker (v)	Seconded By (v)	YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.					
3	Doad, Gurinder J.S., M.D., Ph.D.-Vice-Chair	✓		✓		
4	Fowler, M. Celeste, Pharm.D., HCMA-Chair					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.					
8	Lesnick, Burton, M.D., FAAP			✓		
9	Lorys, Robyn, Pharm.D.			✓		
10	May, J. Russell (Rusty), Pharm.D.			✓		
11	Miller, Osgood (Drew) A., R.Ph.			✓		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.		✓	✓		
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			✓		
TOTAL				7	0	0



## Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective January 1, 2024 (see chart below)\*

DCH rebate vendor, Magellan Medicaid Administration (MMA), has reviewed specific drugs at the September 2023 DURB meeting and corresponding supplemental rebate offers. The Preferred Drug List (PDL)/Provider's Administered Drug List (PADL) decisions/changes for categories reviewed are outlined below. For a full listing of our PDL, go to [www.dch.georgia.gov/pharmacy](http://www.dch.georgia.gov/pharmacy) and select the "Preferred Drug Lists" option; for the PADL, go to <https://www.mmis.georgia.gov/portal/> and select "Provider Information", "Fee Schedule", then "Provider's Administered Drug List."

PREFERRED AGENTS	NON-PREFERRED AGENTS
ALZHEIMER'S AGENTS	
	LEQEMBI (INTRAVEN)* - PA
DISEASE MODIFIER, T1DM	
	TZIELD (INTRAVEN)* - PA
HIV / AIDS	
	SUNLENCA TABLET (ORAL) - PA
	SUNLENCA (SUBCUT)* - PA
	TROGARZO (INTRAVEN)* - PA
MULTIPLE SCLEROSIS AGENTS	
BRIUMVI (INTRAVEN.)* - PA	

\*PADL drugs may be subject to a different effective date.



## Georgia Department of Community Health (GDCH) Opportunities for Pharmaceutical Manufacturer Input on Clinical Recommendations and Clinical Management Strategies by the Drug Utilization Review Board

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

### **Ongoing Opportunity:**

**DUR Board Meeting Process:** New drugs under review will be posted to the DCH website at <https://dch.georgia.gov/providers/provider-types/pharmacy/drug-utilization-review-board/2023-durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) and reported as appropriate by NHC at subsequent DURB meetings.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

### **Opportunity to Appeal to GDCH:**

**GDCH Review Process:** DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmory Hodges at (404) 656-4044 or [shodges@dch.ga.gov](mailto:shodges@dch.ga.gov)**

### **Presentation Opportunity:**

**Manufacturers' Forum:** A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at

<http://dch.georgia.gov/durb-meeting-information>.

Questions not addressed in this document may be sent to NorthStar HealthCare Consulting by e-mail: [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com)

# 2024

## Upcoming Meetings

### Drug Utilization Review Board Meeting

2 Martin Luther King Jr. Drive, S.E.

Atlanta, Georgia 30334

Department of Community Health Board Room - Room 470-A  
East Tower, Balcony Level

Wednesday, April 17, 2024: 10:00am – 2:00pm

Wednesday, July 17, 2024: 10:00am – 2:00pm

Wednesday, October 16, 2024: 10:00am – 2:00pm

*This page intentionally left blank*

# Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise	Company Name
<b>M. Celeste Fowler, Chair</b>	Pharm.D., HCMB	340B Pharmacy	Piedmont Henry Hospital
<b>Gurinder J.S. Doad, Vice-Chair</b>	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
<b>Douglas C. Collins</b>	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
<b>Alton Condra III</b>	R.Ph.	HIV/AIDS Pharmacy - Infectious Disease Program	Grady Memorial Hospital
<b>Otto C. Goyco</b>	M.D., FACP	Internal Medicine	Otto C. Goyco Internal Medicine, LLC
<b>Torey A. Jones</b>	Pharm.D., MBA	340B Pharmacy	Phoebe Putney Health System, Bizzell Group, LLC,
<b>Burton L. Lesnick</b>	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
<b>Robyn Lorys</b>	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
<b>J. Russell May</b>	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
<b>Drew A. Miller</b>	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
<b>Matthew Perri III</b>	Ph.D., R.Ph.	Academia - Professor	University of Georgia College of Pharmacy
<b>Brent L. Rollins</b>	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
<b>Danny A. Toth</b>	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC
<b>Suzanne M. Walton</b>	Pharm.D., BCPS, BCO	Hematology/Oncology	Grady Health System
<b>Glenda Wrenn</b>	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine